Caplin Point Q1 FY27 Results: Profit up 19% to ₹179 cr

Caplin Point posts higher Q1 FY27 profit

Caplin Point Laboratories reported a stronger first quarter of FY27, with consolidated net profit rising to ₹179.09 crore for the quarter ended June 30, 2026. The profit increase of 18.8% year-on-year was compared with ₹150.76 crore in Q1 FY26. The update came through a regulatory filing and associated disclosures around the quarterly results. Alongside profit growth, the company also reported higher operating performance, as reflected in its EBITDA and profit before tax. The results matter for investors tracking earnings momentum in the Indian pharma and export-focused formulations space. The company also announced a post-results conference call on the same day to take investor and analyst questions.

Board approval and regulatory compliance

The company said its Board of Directors met on August 12, 2026 and approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The approval was stated to be in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Caplin Point also noted that the results were reviewed by its Statutory Auditors, Brahmayya & Co. The auditors issued a limited review report pursuant to Standard on Review Engagements (SRE) 2410. These steps are part of the standard quarterly reporting framework for listed companies. The filing also referenced disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which is commonly used for material events and communications to shareholders.

Profit, EBITDA and PBT: key quarterly performance metrics

Caplin Point’s operational performance improved in the June quarter alongside higher profitability. EBITDA rose 23.0% year-on-year to ₹247.0 crore, according to the disclosed highlights. Profit before tax (PBT) increased 22.1% to ₹225.23 crore. Basic earnings per share (EPS) also increased, rising 15.8% to ₹23.27 from ₹20.10 in the corresponding quarter of the previous year. Together, these figures indicate the company saw gains not only in profit but also in operating earnings and pre-tax profitability in the period. The disclosure did not attribute the performance to specific business drivers in the provided text, but the metrics point to stronger operating leverage versus last year’s base.

Revenue and expense snapshot from the quarterly dataset

The article also included a quarterly dataset table with line items such as total revenue, operating income, and expenses for fiscal periods labeled Jun 25, Mar 26, and Jun 24. In that table, total revenue for Jun 25 was listed at ₹510.22 crore versus ₹458.96 crore for Jun 24, showing a year-on-year comparison of 11.17%. Operating income was ₹161.47 crore in Jun 25 versus ₹135.85 crore in Jun 24, with an 18.86% year-on-year comparison shown in the table. Total operating expense was listed at ₹348.75 crore in Jun 25 and ₹323.11 crore in Jun 24. Net income in the same dataset line was shown at ₹152.80 crore (Jun 25) and ₹123.98 crore (Jun 24). Since the article separately states Q1 FY27 net profit at ₹179.09 crore for the quarter ended June 30, 2026, readers should rely on the quarter-specific disclosure when tracking Q1 FY27, while treating the dataset as an additional comparative snapshot presented by the source.

Post-results conference call: timing and dial-in details

Caplin Point said it will host a post-results conference call on August 12, 2026 at 4:30 PM IST to discuss financial performance for the quarter ended June 30, 2026. The call was presented as an opportunity for investors and analysts to review Q1 FY27 results. The announcement also included conference call access numbers, including universal access numbers and international toll-free options.

Share price references reported by the source

The article included two share price references for Caplin Point Laboratories. One line stated the “current share price” as Rs 2625.8. Another line stated that Caplin Point Laboratories share price was ₹2,478 as on 12 August, 2026 at 14:35. Since both numbers were presented in the provided text, readers should treat them as point-in-time references from the data source rather than a single definitive close price.

Dividends and corporate actions mentioned

A corporate actions table in the text showed dividend history entries, including an interim dividend of Rs. 4.00 per share (200%) dated 2026-05-30. It also listed a final dividend of Rs. 3.00 per share (150%) dated 2025-09-12. Separately, a schedule line in the provided table showed “2026-08-12 | Quarterly Results & Final Dividend”, but no dividend amount was stated against that date in the visible text.

Trading window closure for insiders

The text also noted a trading window closure for Caplin Point Laboratories. It stated that the trading window would close from July 01, 2026 for the finalization of unaudited financial results for the quarter ended June 30, 2026. It further stated the window would reopen 48 hours after the financial results are declared. Such disclosures are commonly used to support insider trading compliance around earnings releases.

Market impact and why the update matters

From a market perspective, the most material points in the disclosure were the year-on-year growth in net profit, EBITDA, and PBT for Q1 FY27, along with higher basic EPS. The conference call timing on the day of results provides a structured forum for analysts to seek clarifications on quarterly drivers and outlook, based on management commentary. The presence of audited-review procedures and explicit SEBI regulation references supports confidence in process and disclosure quality, though the results themselves are unaudited. Dividend history references, including the interim dividend earlier in 2026, add context for income-focused shareholders, but the article did not provide a new dividend amount for the current quarter.

Key facts at a glance

Conclusion

Caplin Point Laboratories’ Q1 FY27 update showed higher profitability and operating earnings, with net profit at ₹179.09 crore and EBITDA at ₹247.0 crore for the June 2026 quarter. The company’s board approved the unaudited results on August 12, 2026, with a limited review by Brahmayya & Co. The next immediate checkpoint for investors is the scheduled post-results conference call on August 12, 2026 at 4:30 PM IST, where management is expected to discuss quarterly performance and address questions from analysts and shareholders.